Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ningetinib in Advanced NSCLC With MET Exon 14 Skipping Mutations
NCT04992858Phase 2Withdrawn
- Sponsor
- Sunshine Lake Pharma
- Start
- Nov 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of ningetinib in non-small cell lung cancer (NSCLC), sponsored by Sunshine Lake Pharma. Planned start Nov 2022; status: withdrawn.
02
Drugs
ningetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04992858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04992858.